DIAGNOS to present at Centurion One Capital 9th Annual Toronto Growth Conference
MWN-AI** Summary
At the Centurion One Capital 9th Annual Toronto Growth Conference on March 5, 2026, DIAGNOS Inc. (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A) is poised to present its innovative approach to early detection of eye-related health issues using advanced AI technology. Focused on transforming the optometry sector, DIAGNOS showcases its proprietary FLAIRE AI platform, which includes the Computer Assisted Retina Analysis (CARA) application. CARA's image enhancement capabilities provide sharper and clearer retinal images, facilitating real-time screening for large patient volumes and leading to improved patient outcomes.
CEO André Larente emphasizes that the use of AI is not intended to replace healthcare professionals but to augment their capabilities, allowing for more precise medical care and enhanced efficiency. With over 300,000 optometry locations worldwide, the market potential for DIAGNOS is significant. Larente notes recent collaborations with key industry players that have validated their technology, particularly enhancing DIAGNOS' visibility in the market.
Additionally, the company's renewed focus on government business initiatives signals an exciting growth opportunity for DIAGNOS. As the healthcare landscape rapidly evolves, the application of AI in diagnostics stands to revolutionize patient care, particularly in eye health. By leveraging extensive data, DIAGNOS seeks to establish itself as a leader in the sector.
For further insights into DIAGNOS and its groundbreaking technologies for early disease detection, investors and interested parties are encouraged to visit www.diagnos.ca and www.sedarplus.com. With its commitment to innovation and improving patient outcomes, DIAGNOS is on a promising growth trajectory within the healthcare technology space.
MWN-AI** Analysis
As we approach the Centurion One Capital 9th Annual Toronto Growth Conference, DIAGNOS Inc. (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A) presents an intriguing investment opportunity in the burgeoning field of healthcare technology, specifically in AI-driven diagnostics for eye health. The company’s commitment to enhancing critical eye-related health outcomes through its FLAIRE platform and innovative solutions such as CARA positions it favorably within the global market for optometry—a sector comprising over 300,000 locations worldwide.
Investors should consider DIAGNOS's recent strategic partnerships and collaborations, which enhance credibility and market penetration, particularly with leading players in the industry. This collaborative model has not only strengthened DIAGNOS’s technology but also broadened its visibility, a key factor in scaling operations. Moreover, the resumption of initiatives related to government business suggests that the company is paving the way for substantial growth, tapping into broader healthcare networks and potentially lucrative contracts.
André Larente, CEO, has aptly highlighted how AI will not replace healthcare professionals but instead enable enhanced precision and efficiency—essential in today’s data-driven healthcare landscape. This alignment with current healthcare trends positions DIAGNOS as a forward-looking entity, catering to a growing concerns about patient outcomes driven by extensive data utilization.
Given the exponential rise in telehealth and AI adoption, DIAGNOS stands at the intersection of technology and patient care, making its growth prospects attractive. Investors looking for opportunities within healthcare technology should evaluate DIAGNOS not only on its technological advancements but also its strategic positioning within a significant market sector. As the demand for AI solutions in healthcare continues to grow, DIAGNOS could represent a valuable addition to a diversified investment portfolio.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
BROSSARD, Quebec, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of critical eye-related health issues using advanced technology based on Artificial Intelligence (AI), is pleased to announce that it will be presenting at the Centurion One Capital 9th Annual Conference in Toronto, Canada March 5th 2026.
This exclusive gathering unites the most significant group of Canadian investors in search of promising investment opportunities. DIAGNOS is involved in this esteemed event to showcase its Artificial Intelligence solution tailored for the medical sector. DIAGNOS aims to illustrate that the market they are targeting has the potential for global success.
“Artificial intelligence isn't set to take the place of doctors; instead, it will enable physicians to deliver improved medical care with higher precision and boost efficiency at unparalleled costs. Given the unprecedented amount of data being produced, Artificial Intelligence can leverage this extensive information to greatly improve patient outcomes,” stated André Larente, CEO of DIAGNOS.
“DIAGNOS is dedicated to transforming eye health through technologies based on Artificial Intelligence,” said André. “Our knowledge in AI-driven diagnostics is enhancing patient outcomes around the globe. The optometry sector includes more than 300,000 locations worldwide. Our recent collaboration with the leading player in the industry has not only confirmed our technology but will also significantly increase our visibility. Furthermore, our initiatives related to government business are starting up again, indicating an exciting growth phase for DIAGNOS.”
About DIAGNOS
DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients.
Additional information is available at www.diagnos.ca and www.sedarplus.com.
This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information, please contact:Mr. André Larente, PresidentDIAGNOS Inc.Tel: 450-678-8882 ext. 224alarente@diagnos.ca
FAQ**
How does Diagnos Inc. DGNOF plan to leverage its recent collaboration with a leading industry player to enhance its visibility and market reach in the eye health sector?
What specific advancements in AI technology has Diagnos Inc. DGNOF implemented in its FLAIRE platform that significantly improve patient outcomes in eye health?
Can you elaborate on the potential government partnerships that Diagnos Inc. DGNOF is pursuing to accelerate its growth phase and expand its market presence?
What competitive advantages does Diagnos Inc. DGNOF believe it holds in the optometry sector, considering there are over 300,000 locations worldwide?
**MWN-AI FAQ is based on asking OpenAI questions about Diagnos Inc. (TSXVC: ADK:CC).
NASDAQ: ADK:CC
ADK:CC Trading
0.0% G/L:
$0.22 Last:
18,502 Volume:
$0.22 Open:
